Table 2 Descriptive results for BCVA, PED height and PED width as mean (SD) at 1st Ranibizumab, switch to Aflibercept, 4 months, 1 year after switch and at last follow up visit
Baseline (1st Ranibizumab) | Switch (1st Aflibercept) | 4 months after switch | 1 year after switch | Last follow-up visit | |
|---|---|---|---|---|---|
BCVA | 56.30 (14.10) | 60.42 (14.90) | 62.26 (16.05) | 62.16 (15.92) | 61.58 (16.40) |
PED height | 374.1 (166.9) | 335.7 (155.4) | 270.1 (129.7) | 285.0 (146.6) | 265.3 (133.3) |
PED width | 2130.5 (774.0) | 2590.8 (819.6) | 2554.2 (790.9) | 2583.9 (834.8) | 2702.3 (847.2) |